Phathom Pharmaceuticals Announces VOQUEZNA Tablets For Erosive GERD And Associated Heartburn Added To Express Scripts National Formularies For Commercial Patients
Portfolio Pulse from Benzinga Newsdesk
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) announced that its VOQUEZNA tablets for Erosive GERD and associated heartburn have been added to Express Scripts' national formularies for commercial plans, effective immediately. VOQUEZNA is the first FDA-approved potassium-competitive acid blocker and a new class of treatment for Erosive GERD in the U.S. in over 30 years. This inclusion is expected to provide access to approximately 60 million covered lives in the U.S. Phathom is also engaging with other major PBMs and health plans to expand coverage and offers co-pay assistance for eligible patients.
February 13, 2024 | 1:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Phathom Pharmaceuticals' VOQUEZNA tablets for Erosive GERD have been added to Express Scripts' national formularies, significantly expanding its commercial reach in the U.S. This move is expected to positively impact Phathom's market penetration and revenue potential.
The inclusion of VOQUEZNA in Express Scripts' national formularies represents a significant commercial milestone for Phathom Pharmaceuticals, likely leading to increased adoption and sales. Given the novel nature of the treatment and the large potential patient base, this development is expected to have a positive short-term impact on Phathom's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100